Phytochemicals in the oncology setting

Current Treatment Options in Oncology

Volumn 11, Issue 3-4, 2010, Pages 95-106

  Ulbricht, Catherine E ^a   Chao, Wendy ^a  

^a Natural Standard   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; DOCETAXEL; EPIGALLOCATECHIN GALLATE; ESSIAC; GREEN TEA EXTRACT; HERBACEOUS AGENT; IRINOTECAN; LYCOPENE; NARCOTIC ANALGESIC AGENT; NIFEDIPINE; PACLITAXEL; PLACEBO; PLANT MEDICINAL PRODUCT; RESVERATROL; RETINOL; SILIBININ; TURMERIC; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

ABDOMINAL DISCOMFORT; ADVANCED CANCER; ANAPHYLAXIS; ANOREXIA; ARTICLE; BLOATING; BREAST CANCER; CANCER FATIGUE; CANCER PREVENTION; CANCER THERAPY; DIARRHEA; DIET SUPPLEMENTATION; DIET THERAPY; DIGESTIVE SYSTEM CANCER; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG QUALITY; DRUG SAFETY; DYSPEPSIA; ECZEMA; EPIGASTRIC BURNING; EPIGASTRIC PAIN; EVIDENCE BASED MEDICINE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GINGER; GINSENG; HEADACHE; HEARTBURN; HERB DRUG INTERACTION; HUMAN; INSOMNIA; LUNG CANCER; METEORISM; NAUSEA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; POSTOPERATIVE NAUSEA AND VOMITING; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RADIATION INJURY; RISK REDUCTION; SILYBUM MARIANUM; SOYBEAN; STANDARDIZATION; STOMACH CANCER; TEA; UNSPECIFIED SIDE EFFECT; URTICARIA; VISCUM ALBUM;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 79951951487     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-010-0130-4     Document Type: Article

References (62)

1. Barnes PM, Bloom B, Nahin RL: Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008, 1-23.
2. Richardson MA, Sanders T, Palmer JL, et al.: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000, 18:2505-2514. (Pubitemid 30432515)
3. Ulbricht C, Cohen L, Lee R: Complementary, alternative, and integrative therapies in cancer care. In Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, edn 9. Edited by Devita VT. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2011 (in press).
4. Block KI, Koch AC, Mead MN, et al.: Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 2007, 33:407-418. (Pubitemid 47324224)
5. Lawenda BD, Kelly KM, Ladas EJ, et al.: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008, 100:773-783. (Pubitemid 351809666)
6. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, Mercier JP, Tetu B, Harel F, Masse B, Vigneault E, Vass S, Del Vecchio P, Roy J: A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005, 97:481-488. (Pubitemid 40590429)
7. Bairati I, Meyer F, Jobin E, et al.: Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer 2006, 119:2221-2224. (Pubitemid 44423684)
8. Ulbricht C, Chao W, Costa D, et al.: Clinical evidence of herb-drug interactions: a systematic review by the Natural Standard Research Collaboration. Curr Drug Metab 2008, 9:1063-1120.
9. Mathijssen R H J, Verweij J, DeBruijn P: Modulation of irinotecan (CPT-11) metabolism by St. John's wort in cancer patients. In American Association for Cancer Research, 93rd Annual Meeting, San Francisco, April 6-10, 2002;2002.
10. Smith P, Bullock JM, Booker BM, et al.: The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004, 24:1508-1514. (Pubitemid 39426346)
11. Natural Standard: The Authority on Integrative Medicine 2010, http://www.naturalstandard.com.
12. Reynolds T: Contamination of PC-SPES remains a mystery. J Natl Cancer Inst 2002, 94:1266-1268.
13. Lai MN, Lai JN, Chen PC, et al.: Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. Am J Kidney Dis 2010, 55:507-518.
14. Frenkel M, Ben Arye E, Baldwin CD, Sierpina V, et al.: Approach to communicating with patients about the use of nutritional supplements in cancer care. South Med J 2005, 98:289-294. (Pubitemid 40381706)
15. World Health Organization.: A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva, Switzerland: WHO Press, 2008.
16. Omenn GS, Goodman GE, Thornquist MD, et al.: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996, 88:1550-1559. (Pubitemid 26374508)
17. Druesne-Pecollo N, Latino-Martel P, Norat T, et al.: Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 2010, 127:172-184.
18. Kaegi E: Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ. 1998, 158:897-902.
19. Bryer E: A literature review of the effectiveness of ginger in alleviating mild-to-moderate nausea and vomiting of pregnancy. J Midwifery Womens Health 2005, 50: e1-e3. (Pubitemid 40103893)
20. Ernst E, Pittler MH: Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth 2000, 84:367-371. (Pubitemid 30114135)
21. Kang SC, Lee CM, Choi H, et al.: Evaluation of oriental medicinal herbs for estrogenic and antiproliferative activities. Phytother Res 2006, 20:1017-1019. (Pubitemid 44763791)
22. Young HY, Liao JC, Chang YS, et al.: Synergistic effect of ginger and nifedipine on human platelet aggregation: a study in hypertensive patients and normal volunteers. Am J Chin Med 2006, 34:545-551.
23. Barton DL, Soori GS, Bauer BA, et al.: Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010, 18:179-187.
24. Kim JH, Park CY, Lee SJ: Effects of sun ginseng on subjective quality of life in cancer patients: a doubleblind, placebo-controlled pilot trial. J Clin Pharm Ther 2006, 31:331-334.
25. McLarty J, Bigelow RL, Smith M, et al.: Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2009, 2:673-682.
26. Tsao AS, Liu D, Martin J, et al.: Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila Pa) 2009, 2:931-941.
27. Nakachi K, Suemasu K, Suga K, et al.: Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 1998, 89:254-261. (Pubitemid 28197289)
28. Golden BE, Lam PY, Kardosh A, et al.: Green tea polyphenols block the anticancer effects of bortezsomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113(23):5927-5937.
29. Giovannucci E: Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999, 91:317-331. (Pubitemid 29102331)
30. Koushik A, Hunter DJ, Spiegelman D, et al.: Intake of the major carotenoids and the risk of epithelial ovarian cancer in a pooled analysis of 10 cohort studies. Int J Cancer 2006, 119:2148-2154. (Pubitemid 44423674)
31. Styczynski J, Wysocki M: Alternative medicine remedies might stimulate viability of leukemic cells. Pediatr Blood Cancer 2006, 46:94-98. (Pubitemid 41779324)
32. Cheung CW, Gibbons N, Johnson DW, Nicol DL: Silibinin-a promising new treatment for cancer. Anticancer Agents Med Chem 2010, 10:186-195.
33. Kleijnen J, Knipschild P: Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine 1994, 1:255.
34. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R: Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001, 7:57-72, 74.
35. Lenartz D, Schierholz JM, Menzel J: Influence of complementary mistletoe lectin therapy in the treatment of malignant glioma. Z Onkol 1999, 31:44.
36. Schaefermeyer G, Schaefermeyer H: Treatment of pancreatic cancer with Viscum album (iscador): a retrospective study of 292 patients 1986-1996. Comp Ther Med 1998, 6:172.
37. McNamee D: Mistletoe extract ineffective in melanoma. Lancet 1999, 354(9184):1101.
38. Grossarth-Maticek R, Ziegler R: Randomised and nonrandomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res 2006, 11:485-495. (Pubitemid 44921394)
39. Semiglasov VF, Stepula VV, Dudov A, et al.: The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2004, 24:1293-1302. (Pubitemid 38624978)
40. Truelsen T, Gronbaek M, Schnohr P, Boysen G: Intake of beer, wine, and spirits and risk of stroke: the Copenhagen city heart study. Stroke 1998, 29:2467-2472. (Pubitemid 28543991)
41. Gronbaek M, Deis A, Sorensen TI, et al.: Mortality associated with moderate intakes of wine, beer, or spirits. BMJ 1995, 310:1165-1169.
42. Guerrero RF, Garcia-Parrilla MC, Puertas B, Cantos-Villar E: Wine, resveratrol and health: a review. Nat Prod Commun 2009, 4:635-658.
43. Le Corre L, Chalabi N, Delort L, et al.: Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 2005, 49:462-471. (Pubitemid 40780393)
44. Ramsey TL, Risinger KE, Jernigan SC, et al.: Estrogen receptor beta isoforms exhibit differences in ligandactivated transcriptional activity in an estrogen response element sequence-dependent manner. Endocrinology 2004, 145:149-160. (Pubitemid 38094510)
45. Ackermann S, Hiller S, Osswald H, et al.: 17beta-Estradiol modulates apoptosis in pancreatic betacells by specific involvement of the sulfonylurea receptor (SUR) isoform SUR1. J Biol Chem 2009, 284:4905-4913.
46. Wietzke JA, Welsh J: Phytoestrogen regulation of a Vitamin D3 receptor promoter and 1, 25-dihydroxyvitamin D3 actions in human breast cancer cells. J Steroid Biochem Mol Biol 2003, 84:149-157. (Pubitemid 36514832)
47. Fukui M, Yamabe N, Zhu BT: Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer 2010, 46:1882-1891.
48. Piver B, Berthou F, Dreano Y, Lucas D: Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci 2003, 73:1199-1213. (Pubitemid 36733564)
49. Shu XO, Zheng Y, Cai H, et al.: Soy food intake and breast cancer survival. JAMA 2009, 302:2437-2443.
50. Guha N, Kwan ML, Quesenberry CP Jr, et al.: Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 2009, 118:395-405.
51. Doyle C, Kushi LH, Byers T, et al.: Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 2006, 56:323-353. (Pubitemid 44903908)
52. Quella SK, Loprinzi CL, Barton DL, et al.: Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000, 18:1068-1074. (Pubitemid 30123785)
53. Dhillon N, Aggarwal BB, Newman RA, et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14:4491-4499.
54. Shehzad A, Wahid F, Lee YS: Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 2010, 343(9):489-499.
55. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006, 6:10.
56. Donatus IA, Vermeulen NP: Cytotoxic and cytoprotective activities of curcumin, effects on paracetamolinduced cytotoxicity, lipid peroxidation and glutathione depletion in rat hepatocytes. Biochem Pharmacol 1990, 39:1869-1875. (Pubitemid 20187320)
57. Sarkar FH: Current trends in the chemoprevention of cancer. Pharm Res 2010, 27:945-949.
58. Amin A, Gali-Muhtasib H, Ocker M, Schneider-Stock R: Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci 2009, 5:1-11.
59. Brownstein MJ: A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA 1993, 90:5391-5393. (Pubitemid 23176165)
60. Jack DB: One hundred years of aspirin. Lancet 1997, 350:437-439. (Pubitemid 27331247)
61. Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995, 55:753-760.
62. Kingston DG, Newman DJ: Taxoids: cancer-fighting compounds from nature. Curr Opin Drug Discov Dev 2007, 10:130-144. (Pubitemid 46438642)